| 000 | 01135 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250513102639.0 | ||
| 264 | 0 | _c19970108 | |
| 008 | 199701s 0 0 eng d | ||
| 022 | _a0195-668X | ||
| 024 | 7 |
_a10.1093/eurheartj/16.suppl_l.81 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _avan Hout, B A | |
| 245 | 0 | 0 |
_aCosts and effects of c7E3 in high risk PTCA patients. An indirect analysis for The Netherlands. _h[electronic resource] |
| 260 |
_bEuropean heart journal _cNov 1995 |
||
| 300 |
_a81-5 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAbciximab |
| 650 | 0 | 4 | _aAngioplasty, Balloon, Coronary |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xeconomics |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin Fab Fragments _xeconomics |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xeconomics |
| 650 | 0 | 4 | _aRisk Factors |
| 700 | 1 | _aSimoons, M L | |
| 773 | 0 |
_tEuropean heart journal _gvol. 16 Suppl L _gp. 81-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/eurheartj/16.suppl_l.81 _zAvailable from publisher's website |
| 999 |
_c8861809 _d8861809 |
||